annb0t
Top 20
Immutep Limited
Media Release
First activity evaluation ofefti as part of triple combination therapy yieldspromising early results
with 72.7% response rate and 90.9% disease control ratein 1stline NSCLC patients
The triple combination therapy has been well tolerated and appears to be safe
SYDNEY, AUSTRALIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a clinical-stage biotechnology company developing novel LAG-3 immu...
>>> Read more: Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
Media Release
First activity evaluation ofefti as part of triple combination therapy yieldspromising early results
with 72.7% response rate and 90.9% disease control ratein 1stline NSCLC patients
The triple combination therapy has been well tolerated and appears to be safe
SYDNEY, AUSTRALIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a clinical-stage biotechnology company developing novel LAG-3 immu...
>>> Read more: Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
